<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mult Scler J Exp Transl Clin</journal-id><journal-id journal-id-type="iso-abbrev">Mult Scler J Exp Transl Clin</journal-id><journal-id journal-id-type="publisher-id">MSO</journal-id><journal-id journal-id-type="hwp">spmso</journal-id><journal-title-group><journal-title>Multiple Sclerosis Journal - Experimental, Translational and Clinical</journal-title></journal-title-group><issn pub-type="epub">2055-2173</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6961141</article-id><article-id pub-id-type="doi">10.1177/2055217319841881</article-id><article-id pub-id-type="publisher-id">10.1177_2055217319841881</article-id><article-categories><subj-group subj-group-type="heading"><subject>MS in the Middle East</subject></subj-group></article-categories><title-group><article-title>Epidemiology and phenotypes of multiple sclerosis in the Middle East
North Africa (MENA) region</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yamout</surname><given-names>Bassem I</given-names></name><xref ref-type="corresp" rid="corresp1-2055217319841881"/><aff id="aff1-2055217319841881">American University of Beirut Faculty of
Medicine, Nehme and Therese Multiple Sclerosis Center, Beirut, Lebanon</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9187-5827</contrib-id><name><surname>Assaad</surname><given-names>Wassim</given-names></name><aff id="aff2-2055217319841881">American University of Beirut Faculty of
Medicine, Nehme and Therese Tohme Multiple Sclerosis Center, Beirut,
Lebanon</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Tamim</surname><given-names>Hani</given-names></name><aff id="aff3-2055217319841881">American University of Beirut Faculty of
Medicine, Department of Biomedical Sciences, Beirut, Lebanon</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mrabet</surname><given-names>Saloua</given-names></name><aff id="aff4-2055217319841881">University Tunis El Manar Faculty of Medicine,
Laboratory of Research Neurodegenerative and Mental Diseases Tunis,
Tunisia</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Goueider</surname><given-names>Riyad</given-names></name><aff id="aff5-2055217319841881">University Tunis El Manar Faculty of Medicine,
Laboratory of Research Neurodegenerative and Mental Diseases Tunis,
Tunisia</aff></contrib></contrib-group><author-notes><corresp id="corresp1-2055217319841881">American University of Beirut Faculty of
Medicine, Nehme and Therese Multiple Sclerosis Center, Lebanon.
<email>yamoutba@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><season>Jan-Mar</season><year>2020</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>2055217319841881</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2019</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="society">SAGE Publications Ltd unless otherwise
noted. Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>Creative Commons Non Commercial CC BY-NC: This article is distributed
under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract abstract-type="short"><p>The Middle East North Africa (MENA) region falls in the low-to-moderate multiple
sclerosis (MS) prevalence zone, with prevalence rates slightly lower than
Southern Europe but much higher than sub-Saharan Africa. However, there is
clearly a trend toward increased MS prevalence over the last few decades,
consistent with the globally rising prevalence of the disease. We analyzed all
data collected from the MENACTRIMS (Middle East North Africa Committee for
Treatment and Research in Multiple Sclerosis) registry by the end of December
2018. A total of 6885 patients were eligible for the study. Overall, the
clinical phenotype of MS in the MENA region was not different from the Western
phenotype except for earlier age at onset and a more aggressive clinical course
leading to earlier disability.</p></abstract><kwd-group><kwd>Multiple sclerosis</kwd><kwd>Middle East North Africa</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-March 2020</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts2</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-2055217319841881"><title>Introduction</title><p>Multiple sclerosis (MS) is an immune-mediated demyelinating disorder affecting
predominantly patients aged 20&#x02013;40 years. The incidence and prevalence rates of MS
continue to rise worldwide, with the highest rates originating from North America
and Europe.<sup><xref rid="bibr1-2055217319841881" ref-type="bibr">1</xref></sup> Most countries from the MENA (Middle East North Africa) region fall in the
low-to-moderate MS prevalence zone, with prevalence rates slightly lower than
Southern Europe but much higher than sub-Saharan Africa.</p></sec><sec id="sec2-2055217319841881"><title>Epidemiology</title><p>We reviewed the most relevant epidemiologic studies published in the MENA region, to
determine the prevalence of MS in this part of the world (<xref rid="table1-2055217319841881" ref-type="table">Table 1</xref>). Most epidemiologic studies
performed before the year 2000 showed low prevalence rates of MS ranging between 3
and 20/100,000, and came mostly from Saudi Arabia, Iraq, Libya, Kuwait, Tunisia and
Jordan.<sup><xref rid="bibr2-2055217319841881" ref-type="bibr">2</xref><xref rid="bibr3-2055217319841881" ref-type="bibr"/><xref rid="bibr4-2055217319841881" ref-type="bibr"/><xref rid="bibr5-2055217319841881" ref-type="bibr"/><xref rid="bibr6-2055217319841881" ref-type="bibr"/><xref rid="bibr7-2055217319841881" ref-type="bibr"/>&#x02013;<xref rid="bibr8-2055217319841881" ref-type="bibr">8</xref></sup> Prevalence started rising during
the first decade of the 21<sup>st</sup> century, with studies from Kuwait, Saudi
Arabia, Palestine and Jordan showing rates in the range of 30&#x02013;38/100,000.<sup><xref rid="bibr9-2055217319841881" ref-type="bibr">9</xref><xref rid="bibr10-2055217319841881" ref-type="bibr"/><xref rid="bibr11-2055217319841881" ref-type="bibr"/>&#x02013;<xref rid="bibr12-2055217319841881" ref-type="bibr">12</xref></sup> The only exception was Oman,
that had a persistently low prevalence rate reaching 4/100,000 in 2005, possibly due
to different genetic factors compared with neighboring Arab countries.<sup><xref rid="bibr13-2055217319841881" ref-type="bibr">13</xref></sup> More recent data from Kuwait, Qatar, Bahrain and United Arab Emirates
revealed a further increase, with prevalence rates currently ranging between 55 and
85/100,000.<sup><xref rid="bibr14-2055217319841881" ref-type="bibr">14</xref><xref rid="bibr15-2055217319841881" ref-type="bibr"/><xref rid="bibr16-2055217319841881" ref-type="bibr"/><xref rid="bibr17-2055217319841881" ref-type="bibr"/>&#x02013;<xref rid="bibr18-2055217319841881" ref-type="bibr">18</xref></sup> A single study from Egypt<sup><xref rid="bibr19-2055217319841881" ref-type="bibr">19</xref></sup> reported in 2013 a low prevalence of 13.7/100,000 in a small city located
south of Egypt near the Sudanese border, possibly reflecting the lower prevalence
rates seen in African countries. Interestingly, Iran has always shown the highest
disease prevalence in the region, increasing from 51.9 in 2010 to 148.1/100,000 in
2017, which might be due to genetic factors related to the different ethnic origins
of the Iranian population.<sup><xref rid="bibr20-2055217319841881" ref-type="bibr">20</xref>,<xref rid="bibr21-2055217319841881" ref-type="bibr">21</xref></sup> It is of note that the methodology to calculate prevalence in
the above-mentioned studies varied widely, from national registry-based to hospital
or community-based studies, while some of the older studies used the Kurtzke
approximation. This approximation estimates MS prevalence by comparing the number of
MS and motor neuron disease patients seen during a defined period of time based on
the assumption that the prevalence rate of motor neuron disease is fixed at
5/100,000.</p><table-wrap id="table1-2055217319841881" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Prevalence of multiple sclerosis in the Middle East North Africa region.</p></caption><alternatives><graphic xlink:href="10.1177_2055217319841881-table1"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">
<italic>n</italic>
</th><th rowspan="1" colspan="1">Prevalence (per 100,000)</th><th rowspan="1" colspan="1">Methodology</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Kuwait</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Alroughani (2013)</td><td align="right" rowspan="1" colspan="1">927</td><td align="right" rowspan="1" colspan="1">
<bold>85</bold>
</td><td rowspan="1" colspan="1">National MS registry</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Alshubaili (2005)</td><td align="right" rowspan="1" colspan="1">253</td><td align="right" rowspan="1" colspan="1">
<bold>31</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Al-Din (1986)</td><td align="right" rowspan="1" colspan="1">27</td><td align="right" rowspan="1" colspan="1">
<bold>7.3</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">Palestinians</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Alter (2006)</td><td align="right" rowspan="1" colspan="1">164</td><td align="right" rowspan="1" colspan="1">
<bold>35.3</bold>
</td><td rowspan="1" colspan="1">National MS registry</td></tr><tr><td rowspan="1" colspan="1">Jordan</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;El-Salem (2006)</td><td align="right" rowspan="1" colspan="1">224</td><td align="right" rowspan="1" colspan="1">
<bold>38.0</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Al-Din (1995)</td><td align="right" rowspan="1" colspan="1">36</td><td align="right" rowspan="1" colspan="1">
<bold>20.0</bold>
</td><td rowspan="1" colspan="1">Hospital based/KA*</td></tr><tr><td rowspan="1" colspan="1">Egypt</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Tallawy (2013)</td><td align="right" rowspan="1" colspan="1">3</td><td align="right" rowspan="1" colspan="1">
<bold>13.7</bold>
</td><td rowspan="1" colspan="1">Community based</td></tr><tr><td rowspan="1" colspan="1">Saudi Arabia</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Al Deeb (2009)</td><td align="right" rowspan="1" colspan="1">150</td><td align="right" rowspan="1" colspan="1">
<bold>30.0</bold>
</td><td rowspan="1" colspan="1">Hospital estimate</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Al Rajeh (1993)</td><td align="right" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">
<bold>4.0</bold>
</td><td rowspan="1" colspan="1">Community based</td></tr><tr><td rowspan="1" colspan="1">Libya</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Radhakrishnan (1985)</td><td align="right" rowspan="1" colspan="1">21</td><td align="right" rowspan="1" colspan="1">
<bold>4.0</bold>
</td><td rowspan="1" colspan="1">Community based</td></tr><tr><td rowspan="1" colspan="1">Tunisia</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Attia (1993)</td><td align="right" rowspan="1" colspan="1">3</td><td align="right" rowspan="1" colspan="1">
<bold>9.0</bold>
</td><td rowspan="1" colspan="1">Community based</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Ammar (2006)</td><td align="right" rowspan="1" colspan="1">372</td><td align="right" rowspan="1" colspan="1">
<bold>20.1</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">Iraq</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hamdi (1975)</td><td align="right" rowspan="1" colspan="1">11</td><td align="right" rowspan="1" colspan="1">
<bold>3.4</bold>
</td><td rowspan="1" colspan="1">Hospital based/KA</td></tr><tr><td rowspan="1" colspan="1">Oman</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Tharakan (2005)</td><td align="right" rowspan="1" colspan="1">30</td><td align="right" rowspan="1" colspan="1">
<bold>4.0</bold>
</td><td rowspan="1" colspan="1">Hospital based/KA</td></tr><tr><td rowspan="1" colspan="1">UAE</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Inshasi (2011)</td><td align="right" rowspan="1" colspan="1">158</td><td align="right" rowspan="1" colspan="1">
<bold>55</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Schiess (2016)</td><td align="right" rowspan="1" colspan="1">318</td><td align="right" rowspan="1" colspan="1">
<bold>64.4</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">Qatar</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Deleu (2013)</td><td align="right" rowspan="1" colspan="1">154</td><td align="right" rowspan="1" colspan="1">
<bold>65</bold>
</td><td rowspan="1" colspan="1">Hospital/government based</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Bahrain</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Alsharoqi (2014)</td><td align="right" rowspan="1" colspan="1">287</td><td align="right" rowspan="1" colspan="1">
<bold>60</bold>
</td><td rowspan="1" colspan="1">Hospital based</td></tr><tr><td rowspan="1" colspan="1">Iran</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Sahraian (2010)</td><td align="right" rowspan="1" colspan="1">8146</td><td align="right" rowspan="1" colspan="1">
<bold>51.9</bold>
</td><td rowspan="1" colspan="1">National MS registry</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Eskandarieh (2017)</td><td align="right" rowspan="1" colspan="1">15672</td><td align="right" rowspan="1" colspan="1">
<bold>148.1</bold>
</td><td rowspan="1" colspan="1">National MS registry</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-2055217319841881"><p>*Kurtzke Approximation</p></fn></table-wrap-foot></table-wrap><p>There is clearly a trend toward increased MS prevalence in the Middle East over the
last few decades, consistent with the globally rising prevalence (<xref ref-type="fig" rid="fig1-2055217319841881">Figure 1</xref>). The Multiple
Sclerosis International Federation Atlas recorded a 10% increase in global
prevalence of MS from 30 to 33/100,000 between 2008 and 2013. The rapid rise of
prevalence rates in the MENA region might be partly due to earlier diagnosis,
especially with the advent of magnetic resonance imaging in the 1980s and the new
McDonald diagnostic criteria.<sup><xref rid="bibr22-2055217319841881" ref-type="bibr">22</xref></sup> On the other hand, prolonged survival resulting from medical advances and new
efficacious MS therapies<sup><xref rid="bibr23-2055217319841881" ref-type="bibr">23</xref></sup> might have increased prevalence simply through more patients with MS reaching
older ages. Marrie et&#x000a0;al. have clearly shown that the rise in MS prevalence in the
province of Manitoba-Canada between 1984 and 2004 was associated with a shift in the
MS population age distribution curve toward older ages.<sup><xref rid="bibr24-2055217319841881" ref-type="bibr">24</xref></sup> However, other factors might be contributing to a direct &#x0201c;true&#x0201d; increase in
MS incidence in the Middle East, such as increased urbanization and migration from
rural areas to large cities. Urbanization is associated with less sun exposure,
higher body weight, improved hygiene, increased stress and smoking, all of which are
potential risk factors for developing MS.<sup><xref rid="bibr25-2055217319841881" ref-type="bibr">25</xref></sup> A single study from Kuwait<sup><xref rid="bibr13-2055217319841881" ref-type="bibr">13</xref></sup> showed that this increase in MS incidence is mostly in females, similar to
what has been demonstrated in other regions of the world.<sup><xref rid="bibr26-2055217319841881" ref-type="bibr">26</xref></sup></p><fig id="fig1-2055217319841881" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>MS Prevalence rates in the MENA region by decade according to published
studies (Each bar represents a single study).</p></caption><graphic xlink:href="10.1177_2055217319841881-fig1"/></fig></sec><sec id="sec3-2055217319841881"><title>Clinical characteristics</title><p>The clinical characteristics of MS in the MENA region have been described in isolated
studies from single countries, most of which included relatively small number of
patients. The Middle East North Africa Committee for Treatment and Research in
Multiple Sclerosis (MENACTRIMS) created in 2016 the MENACTRIMS registry as a
regional substudy of MSBase, with the aim of recruiting patients with MS from
different countries in the MENA region. MSBase is an international observational MS
cohort study, registered with the World Health Organization International Clinical
Trials Registry Platform,<sup><xref rid="bibr27-2055217319841881" ref-type="bibr">27</xref></sup> and uses the Imed&#x000a9; software system,<sup><xref rid="bibr28-2055217319841881" ref-type="bibr">28</xref></sup> a clinical database where different demographic, clinical and laboratory
variables are collected. A total of 11 centers joined the MENACTRIMS registry,
contributing 6885 patients as of December 2018.</p><p>We performed an analysis of all data collected up to the end of year 2018. The
Statistical Package for Social Sciences (SPSS), version 24.0 was used for data
cleaning, management and analyses. Descriptive statistics were summarized by
presenting the number and percentage for categorical variables, whereas continuous
ones were presented by mean and standard deviation (&#x000b1;SD). In the bivariate analysis,
the association between relapsing onset and progressive onset MS phenotypes and
other categorical variables was assessed using the Chi-square test, whereas
Student&#x02019;s <italic>t</italic>-test was used for the association between age and
phenotype. The time to reach an Expanded Disability Status Scale (EDSS) score of 6.0
was analyzed using Kaplan&#x02013;Meier survival analysis. A <italic>p</italic>-value
&#x0003c;0.05 was used to indicate statistical significance.</p><p>Mean age at onset was 27.8 (&#x000b1;9.3) and at diagnosis 31.6 (&#x000b1;10.1) years, with an
approximate 3.5 years delay in diagnosis (<xref rid="table2-2055217319841881" ref-type="table">Table 2</xref>). Almost 60% of patients started
below 30 and 17% below 20 years of age. The proportion of females in our registry
was 72.3%, and a positive family history of MS was reported in 17.8% of patients.
Presenting symptoms were spinal in 34.2%, optic in 24.5%, brainstem/cerebellar in
22.3% and supratentorial in 20.0%. Onset was relapsing in 96.1% and progressive in
3.2%. A total of 161 cases of neuromyelitis optica spectrum disorder (NMOSD) were
identified in the registry, accounting for 4.7% of all patients and an NMOSD/MS
ratio of around 1:40.</p><table-wrap id="table2-2055217319841881" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Demographic and clinical characteristics.</p></caption><alternatives><graphic xlink:href="10.1177_2055217319841881-table2"/><table frame="hsides" rules="groups"><tbody valign="top"><tr><td rowspan="1" colspan="1">Age at onset in years (mean&#x02009;&#x02009;&#x000b1;&#x02009;&#x02009;SD),
(<italic>n</italic>&#x02009;=&#x02009;688)</td><td align="center" rowspan="1" colspan="1">27.8 (&#x000b1;9.3)</td></tr><tr><td rowspan="1" colspan="1">Age at diagnosis in years (mean&#x02009;&#x000b1;&#x02009;SD),
(<italic>n</italic>&#x02009;=&#x02009;6885)</td><td align="center" rowspan="1" colspan="1">31.6 (&#x000b1;10.1)</td></tr><tr><td rowspan="1" colspan="1">Gender % (<italic>n</italic>&#x02009;=&#x02009;6885)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">27.7</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">72.3</td></tr><tr><td rowspan="1" colspan="1">Initial Course % (<italic>n</italic>&#x02009;=&#x02009;6885)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Relapsing</td><td align="center" rowspan="1" colspan="1">96.1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Progressive</td><td align="center" rowspan="1" colspan="1">3.2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Undetermined</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td rowspan="1" colspan="1">Family History of MS % (<italic>n</italic>&#x02009;=&#x02009;2641)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">17.8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">82.2</td></tr><tr><td rowspan="1" colspan="1">Employment % (<italic>n</italic>&#x02009;=&#x02009;3725)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Unemployed/retired</td><td align="center" rowspan="1" colspan="1">10.1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Employed</td><td align="center" rowspan="1" colspan="1">46</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Student</td><td align="center" rowspan="1" colspan="1">7.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Housewife</td><td align="center" rowspan="1" colspan="1">36.6</td></tr><tr><td rowspan="1" colspan="1">Education % (<italic>n</italic>&#x02009;=&#x02009;3851)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Elementary</td><td align="center" rowspan="1" colspan="1">21.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;High School</td><td align="center" rowspan="1" colspan="1">44.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;University</td><td align="center" rowspan="1" colspan="1">34</td></tr><tr><td rowspan="1" colspan="1">Symptoms at Onset % (<italic>n</italic>&#x02009;=&#x02009;6885)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Supratentorial</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Optic Pathway</td><td align="center" rowspan="1" colspan="1">26.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Brainstem/Cerebellar</td><td align="center" rowspan="1" colspan="1">22.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Spinal</td><td align="center" rowspan="1" colspan="1">34.2</td></tr></tbody></table></alternatives></table-wrap><p>Comparing primary progressive MS (PPMS) and relapsing&#x02013;remitting MS (RRMS) (<xref rid="table3-2055217319841881" ref-type="table">Table 3</xref>), patients with
PPMS were older (35.1&#x000b1;10.1 vs. 27.7&#x000b1;9.1 years, <italic>p</italic>-value &#x0003c;0.0001),
and more likely to present with spinal symptoms (49.3% vs. 33.7%,
<italic>P</italic>-value &#x0003c;0.0001) rather than optic neuritis (11.4% vs. 26.9%,
<italic>P</italic>-value&#x0003c;0.0001).</p><table-wrap id="table3-2055217319841881" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Comparison of clinical characteristics of patients with relapsing and
progressive onset MS.</p></caption><alternatives><graphic xlink:href="10.1177_2055217319841881-table3"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Relapsing Onset(<italic>n</italic>&#x02009;=&#x02009;6666)</th><th rowspan="1" colspan="1">Progressive Onset(<italic>n</italic>&#x02009;=&#x02009;219)</th><th colspan="2" rowspan="1"><italic>p</italic>-value</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Gender (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">26.9</td><td align="center" rowspan="1" colspan="1">52.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">73.1</td><td align="center" rowspan="1" colspan="1">47.9</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age at onset, years (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="center" rowspan="1" colspan="1">27.7 (9.1)</td><td align="center" rowspan="1" colspan="1">35.1 (10.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Symptoms at onset (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Supratentorial</td><td align="center" rowspan="1" colspan="1">1316 (19.7)</td><td align="center" rowspan="1" colspan="1">61 (27.9)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Optic pathways</td><td align="center" rowspan="1" colspan="1">1792 (26.9)</td><td align="center" rowspan="1" colspan="1">25 (11.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Brainstem</td><td align="center" rowspan="1" colspan="1">1481 (22.2)</td><td align="center" rowspan="1" colspan="1">51 (23.3)</td><td align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Spinal cord</td><td align="center" rowspan="1" colspan="1">2245 (33.7)</td><td align="center" rowspan="1" colspan="1">109 (49.3)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Time to EDSS 6.0*, median (range) in years</td><td align="center" rowspan="1" colspan="1">15.7 (12.4 &#x02013; 20.1)</td><td align="center" rowspan="1" colspan="1">13.3 (11.2 &#x02013; 16.6)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr></tbody></table></alternatives></table-wrap><p>In order to assess the long-term course of the disease, we selected patients with at
least 10 years of follow-up since onset of symptoms (<xref rid="table3-2055217319841881" ref-type="table">Table 3</xref>). A total of 741 patients were
eligible for the analysis. Irreversible disability was defined as persistence of an
EDSS score for two consecutive visits at least 6 months apart. Median time to reach
an EDSS score of 6 was 15.7 (12.4&#x02013;20.1) and 13.3 (11.2&#x02013;16.6) years, respectively,
for the RRMS and PPMS groups.</p><p>Compared with recent epidemiological studies from the West, our patients had a
younger mean age at onset: 27.8 years vs. 30.5 years in Italy, 32.5 years in France
and 30.0 years in the UK.<sup><xref rid="bibr29-2055217319841881" ref-type="bibr">29</xref><xref rid="bibr30-2055217319841881" ref-type="bibr"/>&#x02013;<xref rid="bibr31-2055217319841881" ref-type="bibr">31</xref></sup> A total of
10.6% had onset of symptoms below the age of 18 as compared with 5.5% in the French
cohort. The proportion of females, however, was similar: 72.3% vs. 71.1% and 67% in
the French and Italian registries, respectively. Patients with PPMS constituted 3.2%
of the total cohort, reflecting a lower proportion compared with modern Western
populations: 10.7% in France, 12.9% in the UK, 12.4% in British Columbia and 6% in
Italy, but similar to Japan (3%).<sup><xref rid="bibr29-2055217319841881" ref-type="bibr">29</xref><xref rid="bibr30-2055217319841881" ref-type="bibr"/>&#x02013;<xref rid="bibr31-2055217319841881" ref-type="bibr">31</xref></sup> However, the possibility of
under-diagnosis of PPMS in our registry could not be ruled out, as the latter&#x02019;s
diagnosis is usually more difficult in clinical practice. The NMOSD/MS ratio in our
cohort was close to what has been reported in the West.<sup><xref rid="bibr33-2055217319841881" ref-type="bibr">33</xref></sup></p><p>Our patients with RRMS reached an EDSS score of 6.0 after a median time of 15.7
years, which is much shorter than what has been described in Western MS populations.
Median time to EDSS 6.0 in RRMS patients was 21 (19&#x02013;24) and 27.3 (16.3&#x02013;39.7) years
in two French studies,<sup><xref rid="bibr34-2055217319841881" ref-type="bibr">34</xref>,<xref rid="bibr35-2055217319841881" ref-type="bibr">35</xref></sup> and 30.3 (28.6&#x02013;32.0) years in British Columbia.<sup><xref rid="bibr32-2055217319841881" ref-type="bibr">32</xref></sup> Similar conclusions were reached by two French studies comparing disability
progression between Caucasian French, French of North African origin and Tunisian
RRMS patients. French patients of North African origin reached an EDSS score of 6.0
almost 10 years earlier compared with French patients of Caucasian origin (17.0 vs.
27.3 years).<sup><xref rid="bibr35-2055217319841881" ref-type="bibr">35</xref></sup> Similarly, French patients of Caucasian origin reached an EDSS score of 6.0
five years later than Tunisian patients (21 vs. 16 years). Our data are indicative
of a more aggressive and disabling MS course in the MENA region compared with the
West.</p><p>Disease-modifying therapies (DMTs) are available to different degrees in the MENA
region countries. Gulf countries and Lebanon have access to nearly all DMTs with
adequate reimbursement by governmental agencies. In the remaining countries, new
DMTs are either not registered or not fully reimbursed by governments. Most MENA
countries, however, have access at least to first-line injectables except for
glatiramer acetate due to its Israeli origin. First-line injectables still account
for almost half of the DMTs used in our region (<xref rid="table4-2055217319841881" ref-type="table">Table 4</xref>). This is followed in descending
frequency by fingolimod, natalizumab, rituximab and dimethyl fumarate. It is of note
that locally manufactured generics, mostly Iranian-produced, are used in the MENA
region. However, as shown in <xref rid="table4-2055217319841881" ref-type="table">Table 4</xref>, they account for less than 4% of the total DMTs used. In total,
76.0% of all patients in the registry were on DMTs.</p><table-wrap id="table4-2055217319841881" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Disease-modifying therapies at last follow-up.</p></caption><alternatives><graphic xlink:href="10.1177_2055217319841881-table4"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1">DMT</th><th rowspan="1" colspan="1">Proportion % (<italic>n</italic>)</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">IFN-&#x003b2;</td><td align="center" rowspan="1" colspan="1">48.7 (2552)</td></tr><tr><td rowspan="1" colspan="1"><bold>&#x02003;</bold>IFN &#x003b2;-1a SC</td><td align="center" rowspan="1" colspan="1">31.3 (800)</td></tr><tr><td rowspan="1" colspan="1"><bold>&#x02003;</bold>IFN &#x003b2;-1a IM</td><td align="center" rowspan="1" colspan="1">39.7 (1012)</td></tr><tr><td rowspan="1" colspan="1"><bold>&#x02003;</bold>IFN &#x003b2;-1b</td><td align="center" rowspan="1" colspan="1">28.6 (730)</td></tr><tr><td rowspan="1" colspan="1"><bold>&#x02003;</bold>Pegylated IFN</td><td align="center" rowspan="1" colspan="1">0.4 (9)</td></tr><tr><td rowspan="1" colspan="1">Fingolimod</td><td align="center" rowspan="1" colspan="1">14.9 (783)</td></tr><tr><td rowspan="1" colspan="1">Natalizumab</td><td align="center" rowspan="1" colspan="1">8.5 (448)</td></tr><tr><td rowspan="1" colspan="1">Rituximab</td><td align="center" rowspan="1" colspan="1">4.8 (249)</td></tr><tr><td rowspan="1" colspan="1">Dimethyl fumarate</td><td align="center" rowspan="1" colspan="1">4.8 (249)</td></tr><tr><td rowspan="1" colspan="1">Glatiramer acetate</td><td align="center" rowspan="1" colspan="1">3.3 (250)</td></tr><tr><td rowspan="1" colspan="1">Generic IFN-B</td><td align="center" rowspan="1" colspan="1">3.2 (172)</td></tr><tr><td rowspan="1" colspan="1">Azathioprine</td><td align="center" rowspan="1" colspan="1">3.0 (168)</td></tr><tr><td rowspan="1" colspan="1">Teriflunomide</td><td align="center" rowspan="1" colspan="1">2.3 (156)</td></tr><tr><td rowspan="1" colspan="1">Mitoxantrone</td><td align="center" rowspan="1" colspan="1">1.4 (121)</td></tr><tr><td rowspan="1" colspan="1">Ocrelizumab</td><td align="center" rowspan="1" colspan="1">1.2 (63)</td></tr><tr><td rowspan="1" colspan="1">Alemtuzumab</td><td align="center" rowspan="1" colspan="1">0.9 (49)</td></tr><tr><td rowspan="1" colspan="1">Biotin</td><td align="center" rowspan="1" colspan="1">0.9 (46)</td></tr><tr><td rowspan="1" colspan="1">Cyclophosphamide</td><td align="center" rowspan="1" colspan="1">0.6 (34)</td></tr><tr><td rowspan="1" colspan="1">Mycophenolate</td><td align="center" rowspan="1" colspan="1">0.5 (26)</td></tr><tr><td rowspan="1" colspan="1">Generic Rituximab</td><td align="center" rowspan="1" colspan="1">0.3 (16)</td></tr><tr><td rowspan="1" colspan="1">Methotrexate</td><td align="center" rowspan="1" colspan="1">0.2 (10)</td></tr><tr><td rowspan="1" colspan="1">Generic Glatiramer Acetate</td><td align="center" rowspan="1" colspan="1">0.2 (12)</td></tr><tr><td rowspan="1" colspan="1">Generic Fingolimod</td><td align="center" rowspan="1" colspan="1">0.1 (4)</td></tr><tr><td rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">0.2% (9)</td></tr><tr><td rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">100% (5230)</td></tr></tbody></table></alternatives></table-wrap><p>Our study has certain limitations, common to all registry-based studies. The data
were collected retrospectively, which might have introduced a bias especially in
determining the course of the disease and its phenotype. In addition, and due to the
nature of the data collected, there were no unified definitions of clinical
phenotypes, disability progression and other clinical parameters. Finally, by
choosing patients with a disease duration of at least 10 years, we might have
introduced a selection bias toward patients with more aggressive disease, as the
latter might be more prone to maintain long-term follow-up.</p><p>In conclusion, the prevalence of MS has been steadily rising in the MENA region over
the past few decades. The clinical phenotype of MS in the MENA region is similar to
what has been described in the West except for an earlier age at onset and a more
aggressive clinical course leading to earlier disability.</p></sec></body><back><sec id="sec4-2055217319841881"><title>Funding</title><p>The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p></sec><sec id="sec5-2055217319841881"><title>Conflict of Interests</title><p>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></sec><sec><title>ORCID iD</title><p>Wassim Assaad <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-9187-5827">http://orcid.org/0000-0002-9187-5827</ext-link></p></sec><ref-list content-type="numbered"><title>References</title><ref id="bibr1-2055217319841881"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch-Henriksen</surname><given-names>N and</given-names></name></person-group><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>PS.</given-names></name></person-group>
<article-title>The changing demographic pattern of multiple sclerosis
epidemiology.</article-title>
<source>Lancet Neurol</source>
<year>2010</year>; <volume>9</volume>(<issue>5</issue>):
<fpage>520</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">20398859</pub-id></mixed-citation></ref><ref id="bibr2-2055217319841881"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Rajeh</surname><given-names>BO</given-names></name><name><surname>Ismail</surname><given-names>H</given-names></name><name><surname>Awada</surname><given-names>A</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A community survey of
neurological disorders in Saudi Arabia: The Thugbah study.</article-title>
<source>Neuroepidemiology</source>
<year>1993</year>; <volume>12</volume>(<issue>3</issue>):
<fpage>164</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">8272177</pub-id></mixed-citation></ref><ref id="bibr3-2055217319841881"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Din</surname><given-names>AS</given-names></name></person-group>El-Khateeb M, Kurdi A, , <etal>et&#x000a0;al</etal>
<article-title>Multiple sclerosis in Arabs in
Jordan.</article-title>
<source>J Neurol Sci</source>
<year>1995</year>; <volume>131</volume>(<issue>2</issue>):
<fpage>144</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">7595639</pub-id></mixed-citation></ref><ref id="bibr4-2055217319841881"><label>4</label><mixed-citation publication-type="journal">Radhakrishnan K, Ashok PP, and Sridharan
R, et al. <article-title>Prevalence and pattern of multiple sclerosis in
Benghazi, north-eastern Libya.</article-title>
<source>J Neurol Sci</source>
<year>1985</year>; <volume>70</volume>(<issue>1</issue>):
<fpage>39</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">4045499</pub-id></mixed-citation></ref><ref id="bibr5-2055217319841881"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Din</surname><given-names>AS.</given-names></name></person-group>
<article-title>Multiple sclerosis in Kuwait: Clinical and epidemiological
study.</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>1986</year>; <volume>49</volume>(<issue>8</issue>):
<fpage>928</fpage>&#x02013;<lpage>931</lpage>.<pub-id pub-id-type="pmid">3746326</pub-id></mixed-citation></ref><ref id="bibr6-2055217319841881"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdi</surname><given-names>TI.</given-names></name></person-group>
<article-title>Multiple sclerosis in Iraq: A clinical and geomedical
survey.</article-title>
<source>J Postgrad Med</source>
<year>1975</year>; <volume>21</volume>(<issue>1</issue>):
<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1177161</pub-id></mixed-citation></ref><ref id="bibr7-2055217319841881"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attia Romdhane</surname><given-names>N,</given-names></name></person-group> Ben Hamida M, Mrabet A, , <etal>et&#x000a0;al</etal>
<article-title>Prevalence study of neurologic disorders
in Kelibia (Tunisia).</article-title>
<source>Neuroepidemiology</source>
<year>1993</year>; <volume>12</volume>(<issue>5</issue>):
<fpage>285</fpage>&#x02013;<lpage>299</lpage>.<pub-id pub-id-type="pmid">8309504</pub-id></mixed-citation></ref><ref id="bibr8-2055217319841881"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammar</surname><given-names>N</given-names></name><name><surname>Gouider-Khouja</surname><given-names>N</given-names></name><name><surname>Hentati</surname><given-names>F.</given-names></name></person-group>
<article-title>[A comparative study of clinical and paramedical aspects of
multiple sclerosis in Tunisia].</article-title>
<source>Rev Neurol (Paris)</source>
<year>2006</year>;
<volume>162</volume>(<issue>6-7</issue>):<fpage>729</fpage>&#x02013;<lpage>733</lpage>.<pub-id pub-id-type="pmid">16840981</pub-id></mixed-citation></ref><ref id="bibr9-2055217319841881"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshubaili</surname><given-names>AF</given-names></name></person-group>, Alramzy K, Ayyad YM, , <etal>et&#x000a0;al</etal>
<article-title>Epidemiology of multiple sclerosis in
Kuwait: New trends in incidence and prevalence.</article-title>
<source>Eur Neurol</source>
<year>2005</year>; <volume>53</volume>(<issue>3</issue>):
<fpage>125</fpage>&#x02013;<lpage>131</lpage>.<pub-id pub-id-type="pmid">15860917</pub-id></mixed-citation></ref><ref id="bibr10-2055217319841881"><label>10</label><mixed-citation publication-type="journal">Al-Deeb S. <article-title>Epidemiology of
MS in Saudi Arabia</article-title>. <source>Multi Scler</source>
<year>2009</year>; <volume>15</volume>(<issue>9-Suppl</issue>): p.
<fpage>S16</fpage>.</mixed-citation></ref><ref id="bibr11-2055217319841881"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>M, </given-names></name></person-group>Kahana E, Zilber N, et&#x000a0;al. <article-title>Multiple sclerosis
frequency in Israel's diverse populations.</article-title>
<source>Neurology</source>
<year>2006</year>; <volume>66</volume>(<issue>7</issue>):
<fpage>1061</fpage>&#x02013;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">16606919</pub-id></mixed-citation></ref><ref id="bibr12-2055217319841881"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Salem</surname><given-names>K</given-names></name></person-group>, Al-Shimmery E, Horany K. , <etal>et&#x000a0;al</etal>
<article-title>Multiple
sclerosis in Jordan: A clinical and epidemiological study.</article-title>
<source>J Neurol</source>
<year>2006</year>; <volume>253</volume>(<issue>9</issue>):
<fpage>1210</fpage>&#x02013;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">16649096</pub-id></mixed-citation></ref><ref id="bibr13-2055217319841881"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tharakan</surname><given-names>JJ</given-names></name><name><surname>Chand</surname><given-names>RP</given-names></name><name><surname>Jacob</surname><given-names>PC.</given-names></name></person-group>
<article-title>Multiple sclerosis in Oman.</article-title>
<source>Neurosciences (Riyadh)</source>
<year>2005</year>; <volume>10</volume>(<issue>3</issue>):
<fpage>223</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">22473263</pub-id></mixed-citation></ref><ref id="bibr14-2055217319841881"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alroughani</surname><given-names>R</given-names></name></person-group>Ahmed SF, Behbahani R, et&#x000a0;al. <article-title>Increasing
prevalence and incidence rates of multiple sclerosis in
Kuwait.</article-title>
<source>Mult Scler</source>
<year>2014</year>; <volume>20</volume>(<issue>5</issue>):
<fpage>543</fpage>&#x02013;<lpage>547</lpage>.<pub-id pub-id-type="pmid">24025709</pub-id></mixed-citation></ref><ref id="bibr15-2055217319841881"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deleu</surname><given-names>D</given-names></name></person-group>Mir D, Al Tabouki A, et&#x000a0;al. <article-title>Prevalence,
demographics and clinical characteristics of multiple sclerosis in
Qatar.</article-title>
<source>Mult Scler</source>
<year>2013</year>; <volume>19</volume>(<issue>6</issue>):
<fpage>816</fpage>&#x02013;<lpage>819</lpage>.<pub-id pub-id-type="pmid">22968545</pub-id></mixed-citation></ref><ref id="bibr16-2055217319841881"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsharoqi</surname><given-names>M</given-names></name><name><surname>Almukhtar</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Abdulla</surname><given-names>F</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Prevalence, demographics and
clinical features of multiple sclerosis in Bahrain.</article-title>
<source>Mult Scler Relat Disord</source>
<year>2014</year>; <volume>3</volume>(<issue>6</issue>):
<fpage>761</fpage>.</mixed-citation></ref><ref id="bibr17-2055217319841881"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inshasi</surname><given-names>J </given-names></name></person-group>and<person-group person-group-type="author"><name><surname>Thakre</surname><given-names>M.</given-names></name></person-group>
<article-title>Prevalence of multiple sclerosis in Dubai, United Arab
Emirates.</article-title>
<source>Int J Neurosci</source>
<year>2011</year>; <volume>121</volume>(<issue>7</issue>):
<fpage>393</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">21463177</pub-id></mixed-citation></ref><ref id="bibr18-2055217319841881"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiess</surname><given-names>N</given-names></name></person-group> Huether K, Fatafta T, , <etal>et&#x000a0;al</etal>
<article-title>How global MS prevalence is changing: A
retrospective chart review in the United Arab Emirates.</article-title>
<source>Mult Scler Relat Disord</source>
<year>2016</year>; <volume>9</volume>:
<fpage>73</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">27645349</pub-id></mixed-citation></ref><ref id="bibr19-2055217319841881"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Tallawy</surname><given-names>HN</given-names></name></person-group> Farghaly W, Badry R, ,
<etal>et&#x000a0;al</etal>
<article-title>Prevalence of multiple sclerosis in Al
Quseir city, Red Sea Governorate, Egypt.</article-title>
<source>Neuropsychiatr Dis Treat</source>
<year>2016</year>; <volume>12</volume>:
<fpage>155</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">26834477</pub-id></mixed-citation></ref><ref id="bibr20-2055217319841881"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahraian</surname><given-names>MA</given-names></name></person-group> Khorramnia S, Ebrahim MM, , <etal>et&#x000a0;al</etal>
<article-title>Multiple
sclerosis in Iran: A demographic study of 8,000 patients and changes over
time.</article-title>
<source>Eur Neurol</source>
<year>2010</year>; <volume>64</volume>(<issue>6</issue>):
<fpage>331</fpage>&#x02013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">21071949</pub-id></mixed-citation></ref><ref id="bibr21-2055217319841881"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskandarieh</surname><given-names>S</given-names></name></person-group> Molazadeh N, Moghadasi AN, , <etal>et&#x000a0;al</etal>
<article-title>The
prevalence, incidence and familial recurrence of multiple sclerosis in
Tehran, Iran.</article-title>
<source>Mult Scler Relat Disord</source>
<year>2018</year>; <volume>25</volume>: <fpage>143</fpage>.<pub-id pub-id-type="pmid">30075407</pub-id></mixed-citation></ref><ref id="bibr22-2055217319841881"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JA.</given-names></name></person-group>
<article-title>Proposed revisions to the McDonald criteria for multiple
sclerosis</article-title>. <source>Mult Scler J</source>
<year>2017</year>; <volume>23</volume>(<issue>S3</issue>):
<fpage>19</fpage>.</mixed-citation></ref><ref id="bibr23-2055217319841881"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodin</surname><given-names>DS, Reder AT, Ebers GC</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Survival in MS: A randomized
cohort study 21 years after the start of the pivotal IFNbeta-1b
trial.</article-title>
<source>Neurology</source>
<year>2012</year>; <volume>78</volume>(<issue>17</issue>):
<fpage>1315</fpage>&#x02013;<lpage>1322</lpage>.<pub-id pub-id-type="pmid">22496198</pub-id></mixed-citation></ref><ref id="bibr24-2055217319841881"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrie</surname><given-names>RA</given-names></name></person-group> Yu N, Blanchard J, ,
<etal>et&#x000a0;al</etal>
<article-title>The rising prevalence and changing age
distribution of multiple sclerosis in Manitoba.</article-title>
<source>Neurology</source>
<year>2010</year>; <volume>74</volume>(<issue>6</issue>):
<fpage>465</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">20071664</pub-id></mixed-citation></ref><ref id="bibr25-2055217319841881"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouhieddine</surname><given-names>TH</given-names></name></person-group> Darwish H, Fawaz L, ,
<etal>et&#x000a0;al</etal>
<article-title>Risk factors for multiple sclerosis and
associations with anti-EBV antibody titers.</article-title>
<source>Clin Immunol</source>
<year>2015</year>; <volume>158</volume>(<issue>1</issue>):
<fpage>59</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">25805657</pub-id></mixed-citation></ref><ref id="bibr26-2055217319841881"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Hernan</surname><given-names>MA.</given-names></name></person-group>
<article-title>Temporal trends in the incidence of multiple sclerosis: A
systematic review.</article-title>
<source>Neurology</source>
<year>2008</year>; <volume>71</volume>(<issue>2</issue>):
<fpage>129</fpage>&#x02013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">18606967</pub-id></mixed-citation></ref><ref id="bibr27-2055217319841881"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butzkueven</surname><given-names>H</given-names></name></person-group> Chapman J, Cristiano E, , <etal>et&#x000a0;al</etal>
<article-title>MSBase: An international, online registry
and platform for collaborative outcomes research in multiple
sclerosis.</article-title>
<source>Mult Scler</source>
<year>2006</year>; <volume>12</volume>(<issue>6</issue>):
<fpage>769</fpage>&#x02013;<lpage>774</lpage>.<pub-id pub-id-type="pmid">17263005</pub-id></mixed-citation></ref><ref id="bibr28-2055217319841881"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechati</surname><given-names>S</given-names></name><name><surname>Peyro-St-Paul</surname><given-names>H.</given-names></name></person-group>
<article-title>
<italic>iMed: a new electronic database for monitoring patients with
multiple sclerosis</italic>
</article-title>. <source>Mult Scler</source>
<year>2001</year>: <volume>7</volume>(<issue>1-Suppl</issue>):
<fpage>31</fpage>.</mixed-citation></ref><ref id="bibr29-2055217319841881"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trojano</surname><given-names>M</given-names></name></person-group>Bergamaschi R, Amato MP, , <etal>et&#x000a0;al</etal>
<article-title>The Italian multiple sclerosis
register</article-title>. <source>Neurol Sci</source>
<year>2018</year>; 40: 155.</mixed-citation></ref><ref id="bibr30-2055217319841881"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vukusic</surname><given-names>S</given-names></name></person-group> Casey R, Rollot F, ,
<etal>et&#x000a0;al</etal>
<article-title>Observatoire Francais de la Sclerose en
Plaques (OFSEP): A unique multimodal nationwide MS registry in
France.</article-title>
<source>Mult Scler</source>
<year>2018</year>; <fpage>1352458518815602</fpage>.</mixed-citation></ref><ref id="bibr31-2055217319841881"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>L</given-names></name></person-group>Kumar G, Nakashima I, ,
<etal>et&#x000a0;al</etal>
<article-title>Multiple sclerosis in Japan appears to be
a milder disease compared to the UK.</article-title>
<source>J Neurol</source>
<year>2015</year>; <volume>262</volume>(<issue>4</issue>):
<fpage>831</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="pmid">25605435</pub-id></mixed-citation></ref><ref id="bibr32-2055217319841881"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremlett</surname><given-names>H</given-names></name><name><surname>Paty</surname><given-names>D</given-names></name><name><surname>Devonshire</surname><given-names>V.</given-names></name></person-group>
<article-title>Disability progression in multiple sclerosis is slower than
previously reported.</article-title>
<source>Neurology</source>
<year>2006</year>; <volume>66</volume>(<issue>2</issue>):
<fpage>172</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">16434648</pub-id></mixed-citation></ref><ref id="bibr33-2055217319841881"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Paul</surname><given-names>F.</given-names></name></person-group>
<article-title>Worldwide prevalence of neuromyelitis optica spectrum
disorders.</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>2018</year>; <volume>89</volume>(<issue>6</issue>):
<fpage>555</fpage>&#x02013;<lpage>556</lpage>.<pub-id pub-id-type="pmid">29436488</pub-id></mixed-citation></ref><ref id="bibr34-2055217319841881"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidhom</surname><given-names>Y,</given-names></name></person-group> Maillart E, Tezenas du Montcel S, , <etal>et&#x000a0;al</etal>
<article-title>Fast
multiple sclerosis progression in North Africans: Both genetics and
environment matter.</article-title>
<source>Neurology</source>
<year>2017</year>; <volume>88</volume>(<issue>13</issue>):
<fpage>1218</fpage>&#x02013;<lpage>1225</lpage>.<pub-id pub-id-type="pmid">28235811</pub-id></mixed-citation></ref><ref id="bibr35-2055217319841881"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debouverie</surname><given-names>M</given-names></name></person-group>Lebrun C, Jeannin S, ,
<etal>et&#x000a0;al</etal>
<article-title>More severe disability of North Africans
vs Europeans with multiple sclerosis in France.</article-title>
<source>Neurology</source>
<year>2007</year>; <volume>68</volume>(<issue>1</issue>):
<fpage>29</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">17200488</pub-id></mixed-citation></ref></ref-list></back></article>